March 5, 2024 | Daily JAM, Jubak Picks, LLY, Morning Briefing, NVO, Volatility |
Back on February 20, I posted a video recommending a buy of Novo Nordisk (NVO). In the video, “Buy GLP-1,” I said that the stock, along with Eli Lilly (LLY) was riding the momentum of increased sales of GLP-1 drugs, originally developed to treat diabetes, as weight-loss drugs. Buy, I said, despite the huge run-up in the shares, because new trials and analysis of existing data were pointing to expanded uses for the drugs. Today, Novo Nordic announced exactly the kind of news that I had talked about.
March 4, 2024 | Daily JAM, PYPL, Top 50 Stocks, Videos |
Today’s Quick Pick is Stripe. Stripe isn’t public yet but will likely go public in late 2024 or in 2025. This is an alert to prepare for this IPO. Stripe started in 2011 and is the “Paypal of its time.” I use both platforms and I find Stripe the more powerful and more user-friendly payment platform. Stripe recently did a private, series H deal that valued the company at $65 billion. Paypal, its major competitor (along with Square), has a market cap of $65 billion. I think this will be a very hot, oversubscribed IPO share you can make a quick profit by flipping the shares on IPO day. The recent Series H offer means that Stripe probably won’t go public until the last half of 2024, at the earliest, or more likely 2025. Which give you time to get your ducks in a row in order to put in a bid for some shares in the offering. Talk to your broker now to ensure you sign all the right paperwork and meet eligibility requirements for IPO offers. If you get that started now, you’ll be able to place an order for IPO shares when they’re available. Stripe revenue is at $14 billion with about 19% of the market share versus 42% for PaylPal. The company has just turned EBITDA profitable, a major milestone. This is an appealing IPO and something to start preparing for even though it may be a little ways down the road.
March 4, 2024 | Daily JAM, Long Term, Morning Briefing |
Way back in 2005, shortly before he became chair of the Federal Reserve, economist Ben Bernanke proposed that the world was seeing a long-term glut of savings. With the world awash in cash as a result of massive numbers of people in the developing world entering the job market, and as the Baby Boom generation (and others) hit its peak earning years, and as relatively low inflation and rising real wages freed up more cash for many consumers, long-term interest rates would stay low and remain low for longer. The thesis looks, in retrospect, to have been massively correct. The global economy did experience a long period of extraordinarily low interest rates, with interest rates turning negative for important chunks of the the world. Now, it looks like the long-term trend has gone into reverse. We’re headed into a period of cash scarcity.
March 3, 2024 | Daily JAM, NTCO, Volatility |
Although I’m selling Natura out of my portfolio and my penny stock list, I do want to keep exposure to global beauty sector, however. I like the high margins and I like the correlation between sales of beauty products and rising incomes in developing economies. My pick for this iteration of my penny stock list is L’Occitane International (LCCTF)
March 2, 2024 | Daily JAM, Short Term |
The coming week I expect a battle for the market’s attention between the continued AI monster momentum story and the macro story on inflation and interest rates.
March 1, 2024 | Daily JAM, Mid Term, Morning Briefing |
Access to auto credit declined in January as credit tightened across all channels and across most lender types compared to December, according to the Dealertrack Credit Availability Index. Investors who pay so much attention to interest rates to predict the trend in consumer spending need to spend more time on the other parts of the current credit crunch, the ability of loans. Consumers who can’t borrow can’t spend no matter how many times the Federal Reserve cuts interest rates.
February 29, 2024 | Daily JAM, Jubak Picks, Videos, Volatility |
Today’s Hot Button Moves NOW video is Buy Viking Therapeutics (VKTX). Last week I suggested that you buy GLP-1 drug stocks like Eli Lilly (LLY) or Novo Nordisk (NVO). This class of diabetes and weight loss drugs is growing rapidly, with $36.5 billion in sales in 2023. Viking Therapeutics, a development-stage biotech company, recently announced Phase 2 trial results for its compound VK2735. This drug has the potential to be the best in its class when it hits the market. The company still has to go through Phase 3 trials and approval, but the data show VK2735 to be more effective at weight loss than its competitors. It could also be one of the few drugs of its kind to be available orally. The current round of trials shows that the drug will need to be injected less frequently than competitors. The company trades with a market cap of $9 billion (in contrast to Lilly’s $720 billion market cap) and is still small enough that it could be bought before the expensive process of taking a drug to market. (Although the company recently raised a secondary offering that would advance marketing plans.) I would buy this up to $100 a share and expect it to continue to zoom as more good news, I expect, on the oral version gets released this quarter. I am adding the stock to my online portfolios today, Thursday, February 29. You can find a write up on this pick on my subscription JubakAM.com and free JubakPicks.com sites.
February 29, 2024 | Daily JAM, Mid Term, Morning Briefing |
The headline, all-items Personal Consumption Expenditures price index, the Federal Reserve’s preferred inflation measure, climbed at a 2.4% year over year rate in January. That was in line with what economists had forecast and down from the 2.6% annual rate in December. The core PCE, that is after stripping out more volatile food and fuel prices, climbed at a 2.8% year over year rate. In December the annual rate of core inflation had been 2.9%. But that was the end of the good news in today’s PCE inflation report.
February 28, 2024 | Daily JAM, Jubak Picks, LLY, Stock Alerts, Volatility |
Yesterday, February 28, development-stage biotech Viking Therapeutics (VKTX) announced results from a Phase 2 training of its GLP-1 weight-loss drug candidate that that showed the potential for the VK2735 compound two move to be best in class in the $36.5 billion (revenue) market for GLP diabetes-control and weight-loss drugs. I will add Viking Therapeutic to my Volatility Portfolio and to my Jubak’s Picks Portfolio today, February 29, with a target price of $150.
February 27, 2024 | Daily JAM, Mid Term, Special Reports |
Can you have your cake and eat it too? That’s basically the question stock investors and traders face now. Is there a way to build a strategy that will put profits in your pocket if the rally that set in at the end of 2023 continues? And that will hedge the downside so the your portfolio won’t tumble if the market does? Or that will at least lose less? Or that might even make some money on its downside bets. I think there is. And that’s the subject of this Special Report. Today Steps 1-3
February 26, 2024 | Daily JAM, Morning Briefing, Short Term |
On Thursday the financial markets get a new monthly PCE inflation report. The PCE, Personal Consumption Expenditures index, is the Federal Reserve’s favorite inflation measure. And Thursday’s report on January inflation could be bad news for the financial markets,
February 24, 2024 | Daily JAM, Short Term |
I think.the market to continue to come to terms with the likelihood that the Federal Reserve will begin to cut interest rates later than expected in 2024 and will make fewer cuts than expected.
